Rosuvastatin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Rosuvastatin and local guidelines before prescribing.
Mechanism
HMG-CoA reductase inhibitor.
Uses
Hypercholesterolaemia, cardiovascular prevention.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Myalgia, raised ALT, proteinuria at high dose, new-onset diabetes.
Interactions
Ciclosporin, gemfibrozil raise levels; warfarin effect increased.
Contraindications and cautions
Active liver disease, severe renal impairment (higher doses)
Monitoring
Lipids, ALT, CK if symptoms
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Lower dose in Asian patients and renal impairment; check CK if muscle symptoms.
More from the textbook: uses, cautions and other points
- Try a lower dose, a different statin (e.g. rosuvastatin), or alternate-day dosing.
Endocrinology: Lipids and obesity - Simvastatin - contraindicated (rhabdomyolysis); use low-dose atorvastatin, rosuvastatin or pravastatin with advice.
ID: HIV, viral hepatitis and blood-borne viruses - Stop simvastatin (check CK); use a statin with fewer interactions at low dose (e.g. rosuvastatin or atorvastatin with advice).
ID: HIV, viral hepatitis and blood-borne viruses
Where it is discussed in the book
- Endocrinology: Lipids and obesity (1 mention)
- ID: HIV, viral hepatitis and blood-borne viruses (2 mentions)